Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer.

ABSTRACT: Triple negative breast cancer (TNBC) is an aggressive subtype of the disease with poor clinical outcomes and limited therapeutic options. Immune checkpoint blockade (CP) has surged to the forefront of cancer therapies with widespread clinical success in a variety of cancer types. However, the percentage of TNBC patients that benefit from CP as a monotherapy is low, and clinical trials have shown the need for combined therapeutic modalities. Specifically, there has been interest in combining CP therapy with radiation therapy where clinical studies primarily with external beam have suggested their therapeutic synergy, contributing to the development of anti-tumor immunity. Here, we have developed a therapeutic platform combining radionuclide therapy (RT) and immunotherapy utilizing a radiola

SUBMITTER: Vito A 

PROVIDER: S-EPMC8124136 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature